Proqr Therapeutics Nv (PRQR)

$2.01

+0.02

(+1.01%)▲

Market is closed - opens 7 PM, 06 May 2024

Insights on Proqr Therapeutics Nv

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 655.0K → 3.19M (in $), with an average increase of 38.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -7.99M → -5.34M (in $), with an average increase of 23.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 50.8% return, outperforming this stock by 55.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.3% return, outperforming this stock by 299.8%

Performance

  • $1.97
    $2.05
    $2.01
    downward going graph

    1.99%

    Downside

    Day's Volatility :3.9%

    Upside

    1.95%

    downward going graph
  • $1.11
    $3.29
    $2.01
    downward going graph

    44.78%

    Downside

    52 Weeks Volatility :66.26%

    Upside

    38.91%

    downward going graph

Returns

PeriodProqr Therapeutics NvSector (Health Care)Index (Russel 2000)
3 Months
-6.51%
-1.1%
0.0%
6 Months
64.75%
10.5%
0.0%
1 Year
-4.74%
5.4%
0.5%
3 Years
-67.53%
14.4%
-21.1%

Highlights

Market Capitalization
163.5M
Book Value
$0.51
Earnings Per Share (EPS)
-0.37
PEG Ratio
0.0
Wall Street Target Price
4.26
Profit Margin
0.0%
Operating Margin TTM
-280.12%
Return On Assets TTM
-14.06%
Return On Equity TTM
-51.33%
Revenue TTM
6.6M
Revenue Per Share TTM
0.08
Quarterly Revenue Growth YOY
171.2%
Gross Profit TTM
4.8M
EBITDA
-34.1M
Diluted Eps TTM
-0.37
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.49
EPS Estimate Next Year
-0.59
EPS Estimate Current Quarter
0.01
EPS Estimate Next Quarter
-0.1

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Proqr Therapeutics Nv(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 111.94%

Current $2.01
Target $4.26

Company Financials

FY18Y/Y Change
Revenue
5.7M
↓ 423.15%
Net Income
-42.2M
↓ 15.45%
Net Profit Margin
-746.69%
↓ 3600.65%
FY19Y/Y Change
Revenue
2.2M
↓ 60.88%
Net Income
-63.6M
↑ 53.81%
Net Profit Margin
-2.9K%
↓ 2188.95%
FY20Y/Y Change
Revenue
298.9K
↓ 87.43%
Net Income
-57.3M
↓ 17.86%
Net Profit Margin
-19.2K%
↓ 16247.08%
FY21Y/Y Change
Revenue
1.5M
↑ 457.2%
Net Income
-69.9M
↑ 32.32%
Net Profit Margin
-4.6K%
↑ 14627.33%
FY22Y/Y Change
Revenue
4.3M
↑ 198.15%
Net Income
-69.5M
↑ 5.21%
Net Profit Margin
-1.6K%
↑ 2947.98%
FY23Y/Y Change
Revenue
6.4M
↑ 58.05%
Net Income
-27.5M
↓ 57.56%
Net Profit Margin
-431.67%
↑ 1175.74%
Q3 FY22Q/Q Change
Revenue
939.7K
↓ 6.73%
Net Income
-24.0M
↑ 66.2%
Net Profit Margin
-2.6K%
↓ 1119.09%
Q4 FY22Q/Q Change
Revenue
880.6K
↓ 14.02%
Net Income
-11.4M
↓ 56.39%
Net Profit Margin
-1.3K%
↑ 1256.88%
Q1 FY23Q/Q Change
Revenue
714.3K
↓ 20.32%
Net Income
-8.7M
↓ 24.84%
Net Profit Margin
-1.2K%
↑ 73.43%
Q2 FY23Q/Q Change
Revenue
1.3M
↑ 83.97%
Net Income
-8.7M
↑ 0.03%
Net Profit Margin
-663.32%
↑ 556.68%
Q3 FY23Q/Q Change
Revenue
1.4M
↑ 13.69%
Net Income
-5.7M
↓ 28.56%
Net Profit Margin
-416.79%
↑ 246.53%
Q4 FY23Q/Q Change
Revenue
3.2M
↑ 133.56%
Net Income
-5.3M
↓ 6.44%
Net Profit Margin
-166.96%
↑ 249.83%
FY18Y/Y Change
Total Assets
126.1M
↑ 107.58%
Total Liabilities
20.1M
↑ 27.35%
FY19Y/Y Change
Total Assets
131.7M
↑ 6.63%
Total Liabilities
26.6M
↑ 35.08%
FY20Y/Y Change
Total Assets
121.4M
↓ 16.0%
Total Liabilities
51.9M
↑ 77.97%
FY21Y/Y Change
Total Assets
237.3M
↑ 112.28%
Total Liabilities
109.1M
↑ 128.41%
FY22Y/Y Change
Total Assets
183.5M
↓ 18.25%
Total Liabilities
113.8M
↑ 10.23%
FY23Y/Y Change
Total Assets
138.0M
↓ 19.45%
Total Liabilities
96.6M
↓ 9.07%
Q3 FY22Q/Q Change
Total Assets
119.7M
↓ 32.01%
Total Liabilities
56.2M
↓ 37.89%
Q4 FY22Q/Q Change
Total Assets
183.5M
↑ 40.74%
Total Liabilities
113.8M
↑ 85.7%
Q1 FY23Q/Q Change
Total Assets
172.3M
↓ 7.77%
Total Liabilities
108.3M
↓ 6.49%
Q2 FY23Q/Q Change
Total Assets
161.5M
↓ 6.34%
Total Liabilities
105.3M
↓ 2.84%
Q3 FY23Q/Q Change
Total Assets
142.0M
↓ 4.02%
Total Liabilities
95.7M
↓ 0.82%
Q4 FY23Q/Q Change
Total Assets
138.0M
↓ 2.84%
Total Liabilities
96.6M
↑ 0.92%
FY18Y/Y Change
Operating Cash Flow
-35.1M
↓ 12.21%
Investing Cash Flow
-356.9K
↑ 157.85%
Financing Cash Flow
101.4M
↑ 232.76%
FY19Y/Y Change
Operating Cash Flow
-49.3M
↑ 43.31%
Investing Cash Flow
-649.7K
↑ 85.9%
Financing Cash Flow
56.2M
↓ 43.37%
FY20Y/Y Change
Operating Cash Flow
-57.9M
↑ 7.03%
Investing Cash Flow
-1.1M
↑ 59.31%
Financing Cash Flow
17.8M
↓ 71.11%
FY21Y/Y Change
Operating Cash Flow
-29.5M
↓ 44.73%
Investing Cash Flow
-481.3K
↓ 54.0%
Financing Cash Flow
155.0M
↑ 843.67%
FY22Y/Y Change
Operating Cash Flow
-73.4M
↑ 163.37%
Investing Cash Flow
-752.0K
↑ 65.18%
Financing Cash Flow
-33.1M
↓ 122.58%
Q3 FY22Q/Q Change
Operating Cash Flow
-15.1M
↑ 3.5%
Investing Cash Flow
-241.8K
↑ 6.49%
Financing Cash Flow
-43.0M
↑ 12156.02%
Q4 FY22Q/Q Change
Operating Cash Flow
-19.1M
↑ 16.07%
Investing Cash Flow
20.4K
↓ 107.72%
Financing Cash Flow
14.7M
↓ 131.46%
Q1 FY23Q/Q Change
Operating Cash Flow
48.8M
↓ 350.8%
Investing Cash Flow
-320.6K
↓ 1647.37%
Financing Cash Flow
-282.4K
↓ 101.88%
Q2 FY23Q/Q Change
Operating Cash Flow
-11.3M
↓ 123.13%
Investing Cash Flow
-320.8K
↑ 0.0%
Financing Cash Flow
-701.6K
↑ 148.26%

Technicals Summary

Sell

Neutral

Buy

Proqr Therapeutics Nv is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Proqr Therapeutics Nv
Proqr Therapeutics Nv
-9.05%
64.75%
-4.74%
-67.53%
-82.49%
Moderna, Inc.
Moderna, Inc.
21.5%
73.44%
-8.79%
-23.24%
361.25%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.52%
14.97%
25.57%
98.37%
178.01%
Novo Nordisk A/s
Novo Nordisk A/s
-2.23%
21.74%
50.76%
232.25%
415.39%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.37%
3.97%
15.22%
87.53%
129.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Proqr Therapeutics Nv
Proqr Therapeutics Nv
NA
NA
0.0
-0.49
-0.51
-0.14
NA
0.51
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.0
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
47.43
47.43
2.4
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.81
28.81
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Proqr Therapeutics Nv
Proqr Therapeutics Nv
Buy
$163.5M
-82.49%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.7B
361.25%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.5B
178.01%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$562.8B
415.39%
47.43
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$103.6B
129.5%
28.81
36.68%

Institutional Holdings

  • Privium Fund Management B.V.

    6.59%

  • Adage Capital Partners Gp LLC

    4.47%

  • EcoR1 Capital, LLC

    3.67%

  • M28 Capital Management LP

    2.35%

  • Dafna Capital Management LLC

    1.16%

  • Macquarie Group Ltd

    0.76%

Corporate Announcements

  • Proqr Therapeutics Nv Earnings

    Proqr Therapeutics Nv’s price-to-earnings ratio stands at None

    Read More

Company Information

proqr therapeutics is a leiden, nl based biotech company focused on developments of drugs to treat genetic disorders. based on a novel proprietary technology we discover and develop drugs to change the lives of patients around the world. founded by industry icons and based on ground breaking science we strive to make a meaningful impact. check out our website for vacancies: www.proqr.com

Organization
Proqr Therapeutics Nv
Employees
156
CEO
Dr. Domenico Valerio Ph.D.
Industry
Health Technology

Discover More

FAQs